Insights From the TRAILBLAZER-ALZ Program: Elevated ARIA Risk with Donanemab Highlights the Need for Vigilant Monitoring

While effective in reducing amyloid plaques, donanemab carries a notable risk of amyloid-related imaging abnormalities (ARIA), underscoring the need for careful patient monitoring and risk management strategies.:

Source: Neurology Read More